156 related articles for article (PubMed ID: 33415416)
21.
Naqvi K; Ravandi F
Leuk Lymphoma; 2019 Aug; 60(8):1866-1876. PubMed ID: 30997851
[TBL] [Abstract][Full Text] [Related]
22. Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
Papadopoulos KP; Ben-Ami E; Patnaik A; Trone D; Li J; Demetri GD
BMC Cancer; 2018 Aug; 18(1):790. PubMed ID: 30081867
[TBL] [Abstract][Full Text] [Related]
23. Quizartinib in the treatment of FLT3-internal-tandem duplication-positive acute myeloid leukemia.
Paul S; DiPippo AJ; Ravandi F; Kadia TM
Future Oncol; 2019 Dec; 15(34):3885-3894. PubMed ID: 31559849
[TBL] [Abstract][Full Text] [Related]
24. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
[TBL] [Abstract][Full Text] [Related]
25. Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies.
Swaisland H; Plummer R; So K; Garnett S; Bannister W; Fabre MA; Dota C; Fielding A
Cancer Chemother Pharmacol; 2016 Oct; 78(4):775-84. PubMed ID: 27553432
[TBL] [Abstract][Full Text] [Related]
26. Assessment of Azeliragon QTc Liability Through Integrated, Model-Based Concentration QTc Analysis.
Burstein AH; Brantley SJ; Dunn I; Altstiel LD; Schmith V
Clin Pharmacol Drug Dev; 2019 May; 8(4):426-435. PubMed ID: 30934161
[TBL] [Abstract][Full Text] [Related]
27. Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study.
Munasinghe W; Stodtmann S; Tolcher A; Calvo E; Gordon M; Jalving M; de Vos-Geelen J; Medina D; Bergau D; Nuthalapati S; Hoffman D; Shepherd S; Xiong H
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1003-1011. PubMed ID: 27709282
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the potential for QTc prolongation in patients with solid tumors receiving nivolumab.
Agrawal S; Waxman I; Lambert A; Roy A; Darbenzio R
Cancer Chemother Pharmacol; 2016 Mar; 77(3):635-41. PubMed ID: 26861469
[TBL] [Abstract][Full Text] [Related]
29. Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone.
Nybakken GE; Canaani J; Roy D; Morrissette JD; Watt CD; Shah NP; Smith CC; Bagg A; Carroll M; Perl AE
Leukemia; 2016 Jun; 30(6):1422-5. PubMed ID: 26585411
[No Abstract] [Full Text] [Related]
30. Phase 1 summary of plasma concentration-QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML.
Blotner S; Chen LC; Ferlini C; Zhi J
Cancer Chemother Pharmacol; 2018 Mar; 81(3):597-607. PubMed ID: 29392451
[TBL] [Abstract][Full Text] [Related]
31. A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
Cooper TM; Cassar J; Eckroth E; Malvar J; Sposto R; Gaynon P; Chang BH; Gore L; August K; Pollard JA; DuBois SG; Silverman LB; Oesterheld J; Gammon G; Magoon D; Annesley C; Brown PA
Clin Cancer Res; 2016 Aug; 22(16):4014-22. PubMed ID: 26920889
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR.
Munasinghe WP; Mittapalli RK; Li H; Hoffman DM; Holen KD; Menon RM; Xiong H
Cancer Chemother Pharmacol; 2017 May; 79(5):915-922. PubMed ID: 28349167
[TBL] [Abstract][Full Text] [Related]
33. Availability of FLT3 inhibitors: how do we use them?
Perl AE
Blood; 2019 Aug; 134(9):741-745. PubMed ID: 31243041
[TBL] [Abstract][Full Text] [Related]
34. Quizartinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: More Patients Make It to Transplant, but Are There Any Other Benefits?
Hunter BD
Transplant Cell Ther; 2021 Feb; 27(2):99-100. PubMed ID: 33781547
[No Abstract] [Full Text] [Related]
35. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
[TBL] [Abstract][Full Text] [Related]
36. Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors.
Olszanski AJ; Smith DC; Camacho LH; Thompson J; Ramalingam SS; Harvey RD; Campos L; Ferry D; Tang S; Gao L; Safran H
Oncologist; 2016 Apr; 21(4):402-3. PubMed ID: 26984445
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy.
Chari A; Munder M; Weisel K; Jenner M; Bygrave C; Petrucci MT; Boccadoro M; Cavo M; van de Donk NWCJ; Turgut M; Demirkan F; Karadogan I; Libby E; Kleiman R; Kuppens S; Bandekar R; Neff T; Heuck C; Qi M; Clemens PL; Goldschmidt H
Adv Ther; 2021 Feb; 38(2):1328-1341. PubMed ID: 33474705
[TBL] [Abstract][Full Text] [Related]
38. Effects of elotuzumab on QT interval and cardiac safety in patients with multiple myeloma.
Passey C; Darbenzio R; Jou YM; Lynch M; Gupta M
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1237-1244. PubMed ID: 27796540
[TBL] [Abstract][Full Text] [Related]
39. A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer.
Jones RL; Bendell JC; Smith DC; Diefenbach K; Lettieri J; Boix O; Lockhart AC; O'Bryant C; Moore KN
Cancer Chemother Pharmacol; 2015 Oct; 76(4):777-84. PubMed ID: 26281907
[TBL] [Abstract][Full Text] [Related]
40. Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens.
Tanneau L; Karlsson MO; Rosenkranz SL; Cramer YS; Shenje J; Upton CM; Morganroth J; Diacon AH; Maartens G; Dooley KE; Svensson EM
Clin Pharmacol Ther; 2022 Oct; 112(4):873-881. PubMed ID: 35687528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
